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The pharmacokinetics of sublingual artemether (ArTiMist) was investigated in two open-label studies. In study 1, 16 healthy
males were randomized to each of four single-dose treatments administered in random order: (i) 15.0 mg of sublingual arte-
mether (5 3.0 actuations), (ii) 30.0 mg of sublingual artemether (10 3.0 mg), (iii) 30.0 mg of sublingual artemether (5 6.0
mg), and (iv) 30.0 mg of artemether in tablet form. In study 2, 16 healthy males were randomized to eight 30.0-mg doses of sub-
lingual artemether given over 5 days as either 10 3.0-mg or 5 6.0-mg actuations. Frequent blood samples were drawn postdose.
Plasma artemether and dihydroartemisinin levels were measured using liquid chromatography-mass spectrometry. Population
compartmental pharmacokinetic models were developed. In study 1, sublingual artemether absorption was biphasic, with both
rate constants being greater than that of the artemether tablets (1.46 and 1.66 versus 0.43/h, respectively). Relative to the tablets,
sublingual artemether had greater bioavailability (>1.24), with the greatest relative bioavailability occurring in the 30.0-mg dose
groups (>1.58). In study 2, there was evidence that the first absorption phase accounted for between 32% and 69% of the total
dose and avoided first-pass (FP) metabolism, with an increase in FPmetabolism occurring in later versus earlier doses but with
no difference in bioavailability between the dose actuations. Sublingual artemether is more rapidly and completely absorbed
than are equivalent doses of artemether tablets in healthy adults. Its disposition appears to be complex, with two absorption
phases, the first representing pregastrointestinal absorption, as well as dose-dependent bioavailability and autoinduction of me-
tabolism with multiple dosing.
Artemether is a semisynthetic artemisinin derivative with po-tent in vitro activities against chloroquine-sensitive and chlo-
roquine-resistant Plasmodium falciparum isolates (1). It is utilized
clinically as an initial intramuscular monotherapy for severe ma-
laria (2) and as an oral therapy in combination with the longer
half-life partner drug lumefantrine for uncomplicated P. falcipa-
rum (3, 4) and Plasmodium vivax (5, 6) infections. Suppository
formulations have been developed that can be used when paren-
teral treatment is not feasible (7), and intravenous administration
is theoretically possible, despite its poor water solubility (8), but
these routes of delivery are not currently in clinical use (9).
In studies involving healthy adult volunteers, orally adminis-
tered artemether has been shown to be rapidly absorbed, with a
mean time to maximum plasma concentration (Tmax) of 1.6 to 3.0
h (10–13). It is extensively metabolized, including a significant
first-pass (FP) contribution by the intestine and liver, to dihydro-
artemisinin (DHA), which may have greater antimalarial activity
than the parent compound (14). The mean terminal elimination
half-life (t1/2) of artemether is 2.6 to 3.1 h (10–13). The rapid
formation and metabolism of DHA mean that its maximum
plasma concentration (Cmax) and terminal elimination t1/2 are
similar to those of artemether.
The absolute oral bioavailability of artemether cannot be esti-
mated, given the lack of an approved intravenous formulation.
Estimates of the relative bioavailabilities of oral versus intramus-
cular artemether have varied substantially (15, 16), in part because
there is marked interindividual pharmacokinetic variability with
both routes of administration. It is likely, given its poor solubility,
that the absolute bioavailability of artemether is much less than
that of the chemically related but water-soluble derivative artesu-
nate, which may be as high as 80% (17).
Sublingual administration has advantages over oral dosing for
drugs that can be given in relatively small doses and which are
absorbed through the oral mucosa (18). Pregastrointestinal ab-
sorption into the internal jugular vein can both reduce the time to
therapeutic plasma concentrations and increase bioavailability by
bypassing gut and hepatic FP metabolism. In addition, the nausea
and vomiting associated with a febrile illness, such as malaria,
which can be exacerbated by oral dosing with fluids or food, are
less of a barrier to treatment with sublingual administration.
ArTiMist (Essential Nutrition Ltd., Brough, England) is a sublin-
gual formulation of artemether in neutral oil that is administered
as a metered sublingual spray and which is being developed as a
candidate for prereferral treatment, especially in young children
(see the accompanying paper [19]). In the present study, the first
of two pharmacokinetic evaluations of this product, the disposi-
tion of ArTiMist relative to that of single-dose oral artemether
given as tablets, as well as its multidose pharmacokinetics, were
examined in healthy adult volunteers.
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MATERIALS AND METHODS
Study site, approvals, and subjects. Study 1 was conducted in Penang,
Malaysia, under approval from the Joint Penang Independent ethics com-
mittee (no. 07-0232). Study 2 was carried out in Pretoria, South Africa,
after approval by both the Medicines Control Council of South Africa
and the Pharma-Ethics Independent Research Ethics Committee (no.
07082267). Both studies enrolled healthy adult males (Malaysians for
study 1 and Africans for study 2) between 18 and 45 years of age who had
a body mass index of between 18 and 29 kg/m2, who had not used any
systemic or topical prescription or nonprescription medication within the
previous 14 days or had been participants in a recent investigational drug
study, who were nonsmokers with an alcohol consumption of14 units/
week, and who had no clinically significant dental or oral pathology. All
participants underwent a detailed medical assessment to confirm eligibil-
ity, and witnessed informed consent was obtained prior to enrollment.
Study procedures. The study design is summarized in Table 1. Study 1
was an open-label, randomized, and crossover study comparing two dif-
ferent doses of an artemether spray (ArTiMist; Essential Nutrition Ltd.,
Brough, England) given at two different concentrations with a single oral
dose of artemether. Sixteen participants were randomized to receive each
of four treatments in random order: (i) a single sublingual administration
of 15.0 mg of ArTiMist through 5 actuations of 3.0 mg/actuation (treat-
ment I), (ii) a single sublingual administration of 30.0 mg of ArTiMist
through 10 actuations of 3.0 mg/actuation (treatment II), (iii) a single
sublingual administration of 30.0 mg of ArTiMist through 5 actuations of
6.0 mg/actuation (treatment III), and (iv) a single oral administration of
30.0 mg of artemether in tablet form (Essential Nutrition Ltd.) (10 mg/
tablet, administered as 3 tablets with 240 ml of water) (treatment IV).
The subjects were studied after a10-h fast on each of the four occa-
sions, which were separated by at least a week. An intravenous cannula
was inserted for blood sampling (5 ml/sample) at 0.0 (immediately prior
to dosing), 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, and 12.0 h.
Water intake was restricted from 1 h prior to dosing to 2 h after dosing,
with the exception of the specified volume administered with the arte-
mether tablets. A cup of soybean milk was given 3 h after dosing, and the
subjects were allowed to eat from 4 h postdose onwards.
Study 2 was an open-label, parallel group, and multidose study. Six-
teen participants were randomized by a computer-generated schedule to
one of two equal groups. The group A participants received eight doses of
30.0 mg of ArTiMist through 10 actuations of 3.0 mg/actuation over 5
days (at 0, 24, 36, 48, 60, 72, 84, and 96 h), and those in group B received
30.0 mg of ArTiMist through 5 actuations of 6.0 mg/actuation on the same
schedule as that of group A. An intravenous cannula was inserted for
blood sampling (5 ml) on (i) day 1 (dose 1) at 0.0 (predose), 0.25, 0.5, 0.75,
1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, and 12.0 h, (ii) days 2, 3, and 4 (doses 2
to 7) at 0.0 (premorning dose), 0.5, 1.0, 2.0, and 4.0 h after the morning
dose and 0.0 (preevening dose) and 1 h after the evening dose, and (iii) day
5 (dose 8) at 0.0 (predose), 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0,
12.0, and 24.0 h. The subjects fasted overnight before doses 1 and 8, with
water restricted from dosing to 2 h afterwards and food restricted until 4 h
after each dose. On days 2, 3, and 4, the subjects were given a single dose
following breakfast and another dose 12 h later after dinner.
In both studies 1 and 2, the weight of the delivery device was measured
before and after each dose so that the actual dose delivered could be
calculated.
Drug assays. The plasma artemether and DHA concentrations were
measured using a high-performance liquid chromatography-tandem
mass spectrometric (LC-MS/MS) method based on that of Shi et al. (20),
with modifications. All chemicals used were of high-performance liquid
chromatography (HPLC) or analytical grade. Briefly, 200 l of human
plasma was mixed with 50 l of internal standard (artemisinin) solution
and extracted with 2 ml of methyl tert-butyl ether. After vortexing and
centrifugation, the upper organic layer was collected and evaporated to
dryness at 40°C under a gentle stream of nitrogen. The sample was then
reconstituted in 200 l of 0.1% formic acid-methanol (50/50 [vol/vol]),
and 5l of the resulting solution was injected onto a Zorbax Eclipse XDB
C18 column (Agilent, Waldbronn, Germany) maintained at 30°C. The
mobile phase was 0.1% formic acid-acetonitrile (30/70 [vol/vol]), with a
TABLE 2 Baseline characteristics of participants in studies 1 and 2
Characteristica Study 1
Study 2
P valuebTotal Group A Group B
n 16 16 8 8
Racial group (no. [%])
Malay 10 (63) 0 (0) 0 (0) 0 (0)
Chinese 5 (31) 0 (0) 0 (0) 0 (0)
Indian 1 (6) 0 (0) 0 (0) 0 (0)
African 0 (0) 16 (100) 8 (100) 8 (100)
Age (median [IQR]) (yr) 22 (18–31) 22 (19–37) 22 (19–37) 22 (20–28) 0.87
Wt (median [IQR]) (kg) 63.6 (45.6–79) 64.8 (52.1–74.5) 67.1 (52.1–74.5) 62.2 (54–73.1) 0.28
Ht (median [IQR]) (cm) 170 (157–181) 171 (161–180) 173 (162–180) 170 (161–180) 0.56
BMI (median [IQR]) (kg/m2) 21.3 (17.9–26.1) 22.3 (18.7–25.6) 22.9 (18.7–25.6) 22 (18.9–22.5) 0.09
a IQR, interquartile range; BMI, body mass index.
b P values relate to comparisons between subjects in groups A and B in study 2.
TABLE 1 Designs and artemether dosing schedules used in studies 1 and 2a
Group Study 1: groups of randomly assigned subjects Study 2: parallel groups
i 15 mg of ArTiMist (5 3.0-mg actuations) 8 30 mg (10 3.0-mg actuations)
ii 30 mg of ArTiMist (10 3.0-mg actuations) 8 30 mg (5 6-mg actuations)
iii 30 mg of ArTiMist (5 6.0-mg actuations)
iv 30-mg artemether tablets
a The times of drug administration and blood sampling are given in the text. The doses in study 1 were given in random order, and the doses in study 2 were each given over 5 days.
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gradient flow rate. Positive ion mode was used to identify artemether,
DHA, and artemisinin, with m/z transitions of 221.2 to 163.2, 221.2 to
163.2, and 283.2 to 219.2 and retention times of 5.1, 2.9, and 3.3 min,
respectively, using the API 3000 LC-MS/MS system (Applied Biosystems,
Foster City, CA, USA).
The calibration curves were linear for both artemether and DHA from
2 to 200 ng/ml (r 0.995, P 0.0001), with between-day and within-day
precision rates of 11% for both analytes at the limit of quantification
(LOQ), as well as at low, medium, and high plasma concentrations. The
LOQ was 2 ng/ml (signal-to-noise ratio, 5), and the limit of detection
was 1 ng/ml (signal-to-noise ratio,3) for both artemether and DHA.
Pharmacokinetic modeling. Loge plasma concentration-time data
sets for artemether and DHA were analyzed by nonlinear mixed-effects
modeling using NONMEM (version 7.2.0; Icon Development Solutions,
Ellicott City, MD, USA) with an Intel Visual Fortran 10.0 compiler. The
Laplacian with interaction estimation method was used, as required for
the M3 method of handling below the limit of quantification (BLQ) data
(21). The minimum value of the objective function (OFV) and visual
predictive checks were used during the model-building process to choose
suitable models. A P value of0.05 was set as the level of significance for
a comparison of the nested models. Allometric scaling for body weight
(BW) was employed a priori, with volume terms multiplied by (BW/70)1.0
and clearance terms by (BW/70)0.75 (22). Residual variability (RV) was
estimated as the additive error for the log-transformed data. Second-
ary pharmacokinetic parameters, including the area under the concen-
tration-time curve from time zero to infinity (AUC0 –) and elimina-
tion half-life (t1/2) for the participants, were obtained from post hoc
Bayesian predictions in NONMEM using the final model parameters.
The base models were parameterized using ka (absorption rate con-
stant), Vc (central volume of distribution), CL (clearance), and Vp and
Q (peripheral volumes of distribution and their respective intercom-
partmental clearances, respectively). The data from the two studies
were modeled separately.
The initial modeling was carried out on the artemether data set alone,
and one-, two-, and three-compartment models (ADVAN2, -4, and -12,
respectively) were assessed. As a double peak was present in many of the
individual plasma concentration-time curves after ArTiMist administra-
tion, a number of absorption models were tested, including single- and
double-phase absorption with bolus, zero-, and first-order rates with and
without an initial lag time. Once a suitable structural model for arte-
mether was established, the DHA plasma concentration-time data were
added, and custom general linear disposition models were constructed
using ADVAN5. Models with FP metabolism during both phases of ab-
sorption, as well with the second phase only, were tested. The modeling of
artemether and DHA was performed simultaneously.
To allow identifiability in the parent drug-metabolite model, the com-
plete conversion of artemether to DHA was assumed (14). Therefore, all
artemether parameters were relative to bioavailability (F), while all DHA
parameters were relative to Fmetabolic conversion (F*). One and two
FIG 1 Schematic representation of the final model demonstrating input from
ArTiMist in gray on the left and artemether tablet formulation in black on the
right, where ka1 and ka2 are the absorption rates for the first and second ab-
sorption phases of ArTiMist, LAG1 and LAG2 are the lag times for the first and
second absorption phases of ArTiMist, CL/FARM is artemether clearance rela-
tive to bioavailability,Vc/FARM is the artemether central volume of distribution
relative to bioavailability, Q/FARM is artemether intercompartmental clearance
relative to bioavailability, Vp/FARM is artemether first peripheral volume of
distribution relative to bioavailability, CL/F*DHA is dihydroartemisinin
(DHA) clearance relative to bioavailability, Vc/F*DHA is the central volume of
distribution for DHA relative to bioavailability, FP is first-pass metabolism,
FARM is the relative bioavailability of artemether, and F*DHA is FARM meta-
bolic conversion of artemether to DHA.
FIG 2 Estimates and 95% confidence interval (CI) for relative bioavailability in study 1 of different study occasions (A), different treatments using scheduled
doses (B), and different treatments using actual doses (C).
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additional compartments were tested for DHA, as well as models estimat-
ing the degree of FP metabolism of artemether to DHA. Once the struc-
tures of the models were established, interindividual variability (IIV), in-
teroccasion variability (IOV), and correlations between the IIV terms
were evaluated for each suitable parameter and included where supported
by the data. IIV was exponentially modeled for all parameters, with the
exception of FP metabolism, for which a logit distribution (with variabil-
ity set to 1) was utilized to ensure the values were between 0 and 1.
For study 1, the relative bioavailability of artemether in the three
ArTiMist arms was estimated in comparison with that of the tablet arte-
mether arm, in which bioavailability was set at unity. This same process
was performed for the calculated actual dose received, as assessed by
weighing the delivery device before and after dosing. In addition, the
relative bioavailabilities of occasions 2, 3, and 4 were estimated, with bio-
availability in the first study occasion set at 1.0. A log-likelihood proce-
dure was then used to determine the 95% confidence intervals of these
estimates.
For study 2, the time-dependent pharmacokinetics of artemether were
assessed using two different approaches. The first approach assumed that
the clearance of artemether increased with subsequent doses, as used pre-
viously for children with malaria treated with artemether-lumefantrine
(23, 24). The second approach considered the time-dependent kinetics to
be attributable to an increase in the FP metabolism of artemether. As
previously described for Chinese patients with malaria (25), this may re-
flect the induction of CYP 3A4 activity in either the gut wall or liver. For
each approach, the data for individual subjects for each dose as well as for
grouped doses (i.e., doses 1 to 4 and doses 5 to 8) were used. The two
approaches were compared before selecting the most appropriate model
to describe the time-dependent pharmacokinetics.
For the model evaluation, plots of observed versus individual- and
population-predicted values and time versus weighted residuals (WRES)
were first assessed. A bootstrap using Perl speaks NONMEM (PSN) with
200 samples was performed, and the parameters derived from this analysis
were summarized as the median and 2.5th to 97.5th percentiles (95%
empirical confidence interval [CI]) to facilitate an evaluation of the final
model parameter estimates. In addition, visual predictive checks (VPCs)
and numerical predictive checks (NPCs) were performed with 1,000 data
sets simulated from the final models. The observed 10th, 50th, and 90th
TABLE 3 Final population pharmacokinetic variable estimates and bootstrap results of artemether and DHA for study 1
Parametera Mean RSE%b Bootstrap median (95% CI)
Objective function value 5.85721 37.090 (326.511–189.691)
Structural model parameters
ka1 (/h) 1.46 10 1.50 (1.26–1.76)
ka2 (/h) 1.66 51 1.62 (1.08–4.38)
ka-tab (/h) 0.43 12 0.431 (0.347–0.533)
LAG1 (h) 0.21 3 0.211 (0.196–0.226)
LAG2 (h) 1.37 7 1.38 (1.26–1.48)
LAGtab (h) 0.13 19 0.134 (0.077–0.167)
RATIO 0.99 46 1.02 (0.681–1.74)
CL/FARM (liters/h/70 kg) 862 19 890 (609–1,140)
Vc/FARM (liters/70 kg) 571 14 590 (471–759)
Q/FARM (liters/h/70 kg) 124 67 110 (46–350)
Vp/FARM (liters/70 kg) 1,695 80 1,210 (387–10,096)
CL/F*DHA (liters/h/70 kg) 768 12 786 (633–981)
V/F*DHA (liters/70 kg) 302 12 306 (251–376)
FPmax (%) 41.7 32 38.2 (20.0–59.9)
FPmin (%) 6.9 76 9.0 (0.1–28.0)
Relative bioavailability of treatment
A 1.36 10 1.36 (1.17–1.65)
B 1.97 11 2.02 (1.58–2.39)
C 1.74 12 1.73 (1.44–2.14)
Variability model parameters (shrinkage [%])
IIV in:
CL/FARM 61 (1) 23 58 (28–77)
CL/F*DHA 17 (16) 27 16 (7–23)
ka1 38 (12) 40 35 (15–59)
ka2 105 (3) 42 100 (47–191)
ka-tab 48 (8) 20 46 (26–63)
IOV in F 25 (30, 5, 7, 7) 12 25 (19–29)
IOV in RATIO 167 (2, 15, 16) 15 166 (136–211)
RV for artemether 44 (10) 8 44 (39–51)
RV for DHA 41 (10) 7 40 (37–46)
a ka1, absorption rate constant for first absorption phase of ArTiMist; ka2, absorption rate constant for second absorption phase of ArTiMist; ka-tab, absorption rate constant for
tablet form of artemether; LAG1, lag time for first absorption phase of ArTiMist; LAG2, lag time for second absorption phase of ArTiMist; LAGtab, lag time for tablet form of
artemether; RATIO, ratio between the first and second absorption phases of ArTiMist; CL/FARM, ARM clearance; Vc/FARM, ARM central volume of distribution; Q/FARM, ARM
intercompartmental clearance; Vp/FARM, ARM first peripheral volume of distribution; CL/F*DHA, DHA clearance; Vc/F*DHA, DHA central volume of distribution; FPmax,
maximum percent first-pass metabolism in the study population using a logit distribution; FPmin, minimum percent first-pass metabolism in the study population using a logit
distribution; FARM, relative bioavailability of ARM; F*DHA, FARM  the metabolic conversion of ARM to DHA; IOV, interoccasion variability; IIV, interindividual variability; RV,
residual variability. IOV and IIV are presented as 100% the square root of the variability estimate.
b RSE, relative standard error.
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percentiles and the fraction of BLQ data observed were plotted with their
respective simulated 95% CIs to assess the predictive performance of the
model and to evaluate any major bias. VPCs were plotted against the time
from the last dose and against the time from the first dose. The shrinkage
of the population variability parameters and residual variability were as-
sessed to help determine whether the models were overparameterized and
to determine the reliability of the diagnostic plots (26).
Statistical analysis. Statistical analysis was performed using R version
2.14.2 (R Foundation for Statistical Computing, Vienna, Austria). Two-
sample comparisons for nonnormally distributed variables were done us-
ing the Mann-Whitney U test. Unless otherwise stated, all P values are
two-tailed and unadjusted for multiple comparisons.
RESULTS
Patient characteristics and study course. The baseline character-
istics of the participants by study number and randomized ther-
apy are summarized in Table 2. In study 2, the two randomized
groups were well matched.
The ArTiMist spray formulation was well tolerated, and there
were no adverse events during either study. In study 1, one partici-
pant was absent on occasion 3 and therefore did not receive the single
sublingual administration of 30.0 mg of ArTiMist via 3.0-mg actua-
tions. All other participants received all doses as scheduled.
Pharmacokineticmodeling. (i) Study 1. In study 1, there were
681 individual plasma artemether and DHA concentrations avail-
able for analysis, and 181 (27%) and 217 (32%), respectively, were
below the limit of quantification (BLQ). As only a single plasma
DHA concentration out of 64 observations was above the LOQ at
12 h postdose, the observations at this time point were not in-
cluded in the analysis.
A two-compartment model for artemether was most appropri-
ate, with no benefit being achieved with additional compartments
(P  0.05). For ArTiMist, biphasic absorption was superior to a
single phase (OFV, 30.474; P 0.001). This was represented by
two separate lag times (LAG1 and LAG2), followed by first-order
absorption with two separate absorption rates (ka1 and ka2) (see
Fig. 1). The ratio of the fraction of the dose absorbed in the first
phase versus the second phase (RATIO) was estimated within
NONMEM. For the tablet formulation, absorption was modeled
with a single first-order absorption (ka-tab) with lag time (LAGtab)
(see Fig. 1), which was slower than both ka1 and ka2 (0.43/h versus
1.46/h and 1.66/h, respectively). The second phase of ArTiMist
absorption occurred approximately 1 h after the drug administra-
tion. A model estimating a bolus input was also tested but was
1% of the total dose and did not improve the overall fit. A single
additional compartment was adequate to describe the disposition
of DHA. The inclusion of FP metabolism in the second absorption
peak for ArTiMist and in the absorption of the tablet form of
artemether significantly improved the fit of the model (OFV,
55.613; P  0.001) and was accompanied by an improvement in
ArTiMist VPC plots.
The IIV was estimable for the clearance of artemether (ARM)
(CL/FARM), DHA clearance (CL/F*DHA), ka1, ka2, and ka-tab, with
values of 61%, 17%, 38%, 105%, and 48%, respectively. There was
no significant correlation between the IIV terms. IIV and IOV
could not be estimated simultaneously for RATIO, and the esti-
mate for IOV was much higher (167%), indicating that most of
the variability was between occasions in the same individual rather
than between different individuals. The IOV of the relative bio-
availability was relatively small, at 25%.
The relative bioavailabilities for the ArTiMist treatments were
significantly higher than that of the tablet formulation (estimate
[95% CI from bootstrap], 1.36 [1.17 to 1.65], 1.97 [1.58 to 2.39],
and 1.73 [1.44 to 2.14] for treatments I, II, and III, respectively).
When the actual dose values were used, the bioavailabilities were
lower but remained statistically significantly higher (estimate
[95% CI from log-likelihood profiling], 1.24 [1.01 to 1.53], 1.75
[1.42 to 2.16], and 1.58 [1.28 to 1.95] for treatments I to III, re-
spectively). There was no significant effect of study occasion on
relative bioavailability, with the 95% CI for estimates encompass-
ing unity (i.e., having no effect) (estimate [95% CI from log-like-
lihood profiling], 1.18 [0.97 to 1.44], 1.01 [0.83 to 1.23], and 1.00
[0.82 to 1.21] for occasions 2, 3, and 4, respectively, compared to
occasion 1 (see Fig. 2).
FIG 3 Goodness-of-fit plots for artemether (A to D) and dihydroartemisinin (DHA) (E to H) for study 1. The observed plasma concentration has been plotted
against population-predicted (A and E) and individual-predicted (B and F) plasma concentrations, weighted residuals against time (C and G), and population-
predicted plasma concentrations (D and H). Data below the limit of quantitation (BLQ) have been separated to assist with visual interpretation.
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The final model parameter estimates and the bootstrap results
for study 1 are summarized in Table 3. The bias was10% for all
fixed- and random-model parameters, with the exception of Vp/
FARM and the minimum percent first-pass metabolism in the
study population using a logit distribution (FPmin), for which it
was30%. Figures 3 and 4 show goodness-of-fit plots and VPCs,
respectively. The apparent bias in the weighted residuals is due to
the increasing number of BLQ observations with time and de-
creasing population-predicted values. The actual 10th, 50th, and
90th percentiles fell within their respective 95% CIs for both arte-
mether and DHA for all doses. The half-lives and AUC0 –s de-
rived post hoc from individual parameters are shown in Table 4.
The distribution and terminal elimination t1/2 for artemether were
0.39 and 10.9 h, respectively, and the elimination t1/2 for DHA was
0.27 h. The AUC0 –/dose (a surrogate for relative bioavailability)
was significantly different between the ArTiMist and tablet for-
mulations (P  0.001 for all comparisons) and for the 15.0-mg
versus 30.0-mg ArTiMist treatments (P 0.01 for both compar-
isons), but there was no significant difference between the
30.0-mg ArTiMist treatments (P  0.05). The median simulated
concentrations of artemether and dihydroartemisinin from the
final model fitted to the study 1 data are shown in Fig. 5.
FIG 4 Prediction-corrected visual predictive check for artemether (A to D) and dihydroartemisinin (DHA) (E to H) (in micrograms per liter on a log10 scale)
separated by treatment (I to IV, from left to right) for study 1, with observed 50th (solid line) and 10th and 90th (dotted lines) percentiles within their simulated
95% CI (gray shaded areas), with overlying data points (Œ). The fractions of BLQ observations from the data (Œ, dashed line) with the simulated 95% prediction
interval are also shown.
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(ii) Study 2. In study 2, there were 720 individual plasma arte-
mether and DHA concentrations available for analysis, and 182
(25%) and 246 (34%), respectively, were BLQ. Given that a signif-
icant majority of the plasma concentration data for artemether
and DHA were below the LOQ from 12 h postdose, these obser-
vations were not included in the analysis.
The initial modeling of the study 2 data generated a structural
model similar to that derived in study 1. This was a two-compart-
ment model for artemether, with a single additional compartment
for DHA. Absorption was characterized by two phases with two
separate lag times (LAG1 and LAG2), followed by first-order ab-
sorption with two separate absorption rates (ka1 and ka2). A
RATIO term was also included. The values for these parameters
were comparable between the two studies (see Tables 3 and 5). As
with study 1, a model estimating bolus input was also tested, but it
was1% of the total dose and did not improve the overall fit.
The models with increasing FP metabolism for subsequent
doses were better than those with increasing clearance for subse-
quent doses in describing the time-dependent kinetics of arte-
mether. A better fit of the data was obtained when FP metabolism
was applied to the second absorption phase only. When FP me-
tabolism was considered for individual doses, it was poorly esti-
mated; therefore, early (doses 1 to 4) and later (doses 5 to 8) doses
were grouped to allow a simple binary comparison. The estimate
for doses 1 to 4 was also poorly estimated, and it was therefore
fixed to the results obtained from study 1. The data did not sup-
port a robust estimation of the parameters when linear, hyperbolic
maximum effect (Emax), and sigmoid Emax models were tested. FP
metabolism was estimated to be doubled for doses 5 to 8 com-
pared to that with doses 1 to 4, with population maximum values
of 82.7% versus 41.7%, respectively.
The IIV was estimable for CL/FARM, CL/F*DHA, and ka1, with
values of 52%, 49%, and 51%, respectively. As for study 1, the IIV
and IOV could not be estimated simultaneously for RATIO, with
a much higher estimate for IOV (146%). The IOV of relative bio-
availability was small, at 30%. These results were consistent with
those of study 1.
The final model parameter estimates and bootstrap results for
study 2 are summarized in Table 5. The bias was10% and 11%
for all fixed- and random-model parameters, respectively, with
the exception of Q/FARM and Vp/FARM, where it was 20% and
30%, respectively. Figures 6 and 7 show goodness-of-fit plots and
VPCs, respectively. The 10th, 50th, and 90th percentiles fell within
their respective 95% CIs for all but one and three time points for
artemether and DHA, respectively. The half-lives and AUC0 –
values derived from post hoc individual parameters are shown in
Table 4. The distribution and terminal elimination t1/2 for arte-
mether were 0.39 and 42.3 h, respectively, and the elimination t1/2
for DHA was 0.27 h. The significantly longer terminal elimination
t1/2 relative to that of study 1 reflects the longer sampling time in
TABLE 4 Derived secondary pharmacokinetic parameters from post hoc individual parameters for studies 1 and 2
Parameter by studya Artemether Dihydroartemisinin Relative bioavailability DHA:ART ratio
Study 1
t1/2	 (h) 0.39 (0.31–0.55) 0.27 (0.25–0.29)
t1/2
 (h) 10.9 (10.1–11.5)
AUC0– (g · h/liter) for treatment:
I 21.5 (15.0–36.1) 28.6 (23.3–33.2) 1.48 1.10–1.84)
II 63.6 (42.5–102) 79.3 (69.0–97.9) 2.01 1.72–2.68)
III 63.4 (39.9–97.0) 74.4 (58.1–87.9) 1.81 1.62–2.06)
IV 29.1 (20.9–51.5) 47.2 (34.4–52.5) 1 (FIXED)
Study 2
t1/2	 (h) 0.39 (0.35–0.43) 0.31 (0.21–0.39)
t1/2
 (h) 42.3 (41–44.8)
AUC0– (g · h/liter)
Doses 1–4 (avg) 72.3 (56.3–93.7) 74.8 (53.2–101) 1.22 (0.924–1.49)
Doses 5–8 (avg) 55.5 (46.3–71.8) 67.6 (51.7–99.7) 1.41 (1.22–1.92)
Total 507 (422–665) 569 (417–806) 1.28 (1.04–1.63)
a t1/2	, first half-life; t1/2
, second half-life; AUC0 –, area under the concentration-time curve from time 0 to infinity.
FIG 5 Median simulated concentrations of artemether (A) and dihydroartemisinin (B) (micrograms per liter on a log10 scale) from the final model for study 1.
Treatment I is represented by a solid gray line, treatment II by a dashed black line, treatment III by a dashed gray line, and treatment IV by a solid black line.
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study 2, which facilitated the further characterization of this phase
of elimination. The median artemether Tmax values for the first
peak of ArTiMist were 0.7 h in study 1 and 0.8 h in study 2 com-
pared to 1.4 h for the tablet formulation in study 1. For the second
peak, the median artemether Tmax values were 1.7 h and 1.5 h for
studies 1 and 2, respectively.
DISCUSSION
The present study shows that artemether administered as the
ArTiMist sublingual spray has20% greater bioavailability than
do artemether tablets given in an equivalent dose to healthy adult
volunteers, and it was also more rapidly absorbed. Pharmacokinetic
modeling showed that the disposition of ArTiMist is relatively com-
plex. It has two absorption phases, with plasma concentration peaks
that both occur earlier than that of the single absorption profile asso-
ciated with the ingestion of artemether tablets. In addition, the first
peak does not involve FP metabolism. Drug absorption during the
first phase accounted for between 32% and 69% (RATIO, 0.48 and
2.23, respectively) of the total dose and was consistent with that seen
in the case of other sublingually absorbed drugs (27). The lower rel-
ative bioavailability of the 15.0-mg dose versus the 30.0-mg ArTiMist
doses, together with a comparison of the present AUC0–/dose data
and those of previously published studies, suggest that artemether has
dose-dependent pharmacokinetics.
The biphasic absorption profile of ArTiMist and the indication
from the present kinetic modeling that FP metabolism occurs only
during the second phase of absorption suggest that there is pre-
gastrointestinal absorption of artemether when it is administered
sublingually to healthy adults. We postulate that during the first
absorption phase, some administered ArTiMist is absorbed from
within the oral cavity (sublingually and perhaps via other parts of
the oral mucosa where the drug is dispersed during or after ad-
ministration), with a plasma concentration peak at around 45
min, and the remainder is swallowed, with a slow transfer into the
upper gastrointestinal tract, resulting in a later plasma concentra-
tion peak approximately 1.5 h after dosing. Given that the rate and
extent of absorption of the tablet formulation will depend on dis-
persion, dissolution in the stomach, and transfer into the upper
small intestine, it is not surprising that the ArTiMist solution is
more rapidly and completely absorbed.
In the multidose study, there was a modest increase in FP arte-
mether metabolism over time. This phenomenon has been ob-
served in previous studies of healthy volunteers (28) and may
reflect the autoinduction of the hepatic enzymes CYP3A4,
CYP3A5, and/or CYP2B6 (29). The magnitude of this effect was
less in the present study than that reported previously (28), with
only a doubling of the extent of FP metabolism. This may reflect
the fact that the plasma concentrations achieved in the present
study were, consistent with the dose administered, less than those
in previous studies (25, 28), with the possibility that higher con-
TABLE 5 Final population pharmacokinetic variable estimates and bootstrap results of ARM and DHA for study 2
Parametera Mean RSE%b Bootstrap median (95% CI)
Objective function value 774.197 802.853 (663.142–926.848)
Structural model parameters
ka1 (/h) 1.81 22 1.72 (1.39–2.24)
ka2 (/h) 0.75 16 0.72 (0.59–1.94)
LAG1 (h) 0.17 9 0.18 (0.14–0.19)
LAG2 (h) 1.32 10 1.32 (0.99–1.40)
RATIO doses 1, 8 2.23 64 1.97 (0.79–12.5)
RATIO doses 2–7 0.48 28 0.42 (0.21–0.90)
CL/FARM (liters/h/70 kg) 410 21 423 (294–633)
Vc/FARM (liters/70 kg) 323 29 308 (179–431)
Q/FARM (liters/h/70 kg) 164 17 130 (92–161)
Vp/FARM (liters/70 kg) 7,270 30 5,075 (3,516–8,476)
CL/F*DHA (liters/h/70 kg) 455 20 475 (357–675)
V/F*DHA (liters/70 kg) 196 27 197 (137–298)
FPmax,doses 1–4 (%) 41.7 Fixed
FPmax,doses 5–8 (%) 82.7 11 78.0 (15.6–92.2)
FPmax-to-FPmin ratio 6.07 Fixed
Variability model parameters (shrinkage [%])
IIV in CL/FARM 52 (4) 24 52 (16–71)
IIV in CL/F*DHA 49 (4) 34 47 (24–72)
IIV in ka1 51 (15) 28 47 (27–78)
IOV in F 30 (18, 24, 27, 30, 49) 24 30 (18–40)
IOV in RATIO 146 (1, 19, 17, 36, 7) 13 145 (105–193)
RV for ART 60 5 59 (54–63)
RV for DHA 78 4 77 (71–82)
a ka1, absorption rate constant for first absorption phase of ArTiMist; ka2, absorption rate constant for second absorption phase of ArTiMist; LAG1, lag time for first absorption
phase of ArTiMist; LAG2, lag time for second absorption phase of ArTiMist; RATIO, ratio between the first and second absorption phases of ArTiMist; CL/FARM, ARM clearance;
Vc/FARM, ARM central volume of distribution; Q/FARM, ARM intercompartmental clearance; Vp/FARM, ARM first peripheral volume of distribution; CL/F*DHA, DHA clearance;
Vc/F*DHA, DHA central volume of distribution; FPmax, doses 1– 4 and FPmax, doses 5– 8, degree of first-pass metabolism for doses 1 to 4 and 5 to 8, respectively; FPmax-to-FPmin
ratio, ratio of the population maximum of FP compared to the population minimum; FARM, relative bioavailability of ARM; F*DHA, FARM  the metabolic conversion of ARM to
DHA; IOV, interoccasion variability; IIV, interindividual variability; RV, residual variability. IOV and IIV are presented as 100% the square root of the variability estimate.
b RSE, relative standard error.
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centrations have a greater effect on autoinduction. However,
given that artemether autoinduction is slower and less marked
than that associated with artemisinin itself (30) and that ArTiMist
as monotherapy should not be given for more than a few doses
with a likely role in prereferral treatment, this phenomenon ap-
pears to be of limited clinical relevance.
The doses used in the present study were the lowest in all pub-
lished pharmacokinetic studies of artemether in healthy volun-
teers, specifically, 0.6 mg/kg of body weight versus 1.6 to 9.6
mg/kg of body weight, respectively (10, 11, 13, 15, 25). The
AUC0 – (in microgram-hours per liter) corrected for dose (in
milligrams per kilogram) was also generally lower in our adult
volunteers, including in those who were allocated artemether tab-
lets (range, 51 to 100 g · h/liter versus 70 to 275 g · h/liter [10,
11, 13, 15, 25]), suggesting that artemether bioavailability was
attenuated at lower doses. This is in accord with the significantly
lower relative bioavailability of the 15.0-mg dose versus 30.0-mg
dose of ArTiMist in the present study and suggests that oral arte-
mether exhibits dose-dependent kinetics.
A possible explanation for this phenomenon relates to the in-
testinal mucosal metabolism of artemether. Studies involving
grapefruit juice administration (31) show that the inhibition of
intestinal CYP3A4 substantially increases plasma artemether con-
centrations. This implies that the normal activity of this enzyme
attenuates bioavailability. This effect may be most pronounced at
low artemether doses but is saturable at higher doses (32). A for-
mal evaluation of this effect was beyond the scope of the present
study, but it may have clinical significance. Inadvertent repeated
underdosing might carry a disproportionate risk of subtherapeu-
tic plasma concentrations of artemether and DHA and increase
the risk of treatment failure if artemether were used as mono-
therapy.
An alternative explanation for the relatively low dose-cor-
rected AUC0 – values in the present study compared with those of
FIG 6 Goodness-of-fit plots for artemether (A to D) and dihydroartemisinin (DHA) (E to H) for study 2. The observed plasma concentration has been plotted
against population-predicted (A and E) and individual-predicted (B and F) plasma concentrations, weighted residuals against time (C and G), and population-
predicted plasma concentrations (D and H). Data below the limit of quantitation (BLQ) have been separated to assist with visual interpretation.
FIG 7 Prediction-corrected visual predictive check for artemether (A) and dihydroartemisinin (DHA) (B) (micrograms per liter on a log10 scale) for study 2,
with observed 50th (solid line) and 10th and 90th (dotted lines) percentiles within their simulated 95% CI (gray shaded areas), with overlying data points (Œ).
The fractions of BLQ observations from the data (Œ, dashed line) with the simulated 95% prediction interval are also shown.
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other published data might be our strict requirement for the sub-
jects to fast. Fat coadministered with the drug increases the bio-
availability of artemether (14). Food was either provided or al-
lowed before or during sampling in some studies (10, 11), and
whether subjects were kept fasting was not specified in others (12,
13). Nevertheless, the one study in which fasting throughout the
8-h sampling period was specified (28) appeared to show greater
bioavailability than that in our subjects.
The terminal elimination t1/2 of artemether in our volunteers
was long relative to that in other studies (10.4 h in our study
versus 2.6 to 3.1 h in others [10–13]). However, our elimination
t1/2 was derived from a two-compartment model rather than the
one-compartment or noncompartmental analyses used in other
healthy adult studies. In a pharmacokinetic study of uncompli-
cated malaria in children in which a two-compartment model was
used, the artemether elimination t1/2 was similarly long (23 h)
(23). This second (terminal) elimination phase contributes20%
to the AUC in the present studies and may reflect the combination
of a long duration of sampling postdose and a relatively sensitive
assay, as we have found with artemisinin itself (30).
In conclusion, ArTiMist is a novel sublingual spray formula-
tion of the well-established antimalarial drug artemether. The
present studies in healthy adults show that it has greater bioavail-
ability and is more rapidly absorbed than is an equivalent dose of
artemether in tablet form. Given that the antimalarial activity of
artemether results from the actions of both artemether and its
active metabolite DHA, ArTiMist dosed sublingually should en-
sure a clinically relevant initial increase in plasma artemether with
an increasing contribution from DHA as artemether is metabo-
lized to the more potent DHA metabolite. The present and
previous studies of artemether disposition provide some evi-
dence that lower doses are associated with reduced bioavail-
ability, but higher oral doses are more potent in promoting
autoinduction, suggesting dose-dependent pharmacokinetics.
However, giving the same dose of ArTiMist in a more concen-
trated solution does not alter its absorption. These pharmaco-
kinetic data justify studies of ArTiMist as an initial therapy for
use in patients with uncomplicated malaria.
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